Impact of IL-6 and IL-10 genotypes on tacrolimus dose requirements in kidney transplant recipients: Monte Carlo analysis

References

• Shuker N, van Gelder T, Hesselink DA. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. Transplant. Rev. (Orlando). 2015;29(2):78–84. doi:10.1016/j.trre.2015.01.002
   PubMedGoogle Scholar
• Brunet M, Pastor-Anglada M. Insights into the pharmacogenetics of tacrolimus pharmacokinetics and pharmacodynamics. Pharmaceutics. 2022;14(9):1755. doi:10.3390/pharmaceutics14091755
   PubMed Web of Science ®Google Scholar
• Velickovic-Radovanovic R, Mikov M, Catic-Djordjevic A, et al. Gender-dependent predictable pharmacokinetic method for tacrolimus exposure monitoring in kidney transplant patients. Eur J Drug Metab Pharmacokinet. 2015;40(1):95–102. doi:10.1007/s13318-014-0184-y
   PubMed Web of Science ®Google Scholar
• Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet. 2010;49(3):141–175. doi:10.2165/11317350-000000000-00000
   PubMed Web of Science ®Google Scholar
• Stefanović N, Veliĉković-Radovanović R, Danković K, et al. Effect of the interrelation between CYP3A5 genotype, concentration/dose ratio and intrapatient variability of tacrolimus on kidney graft function: monte carlo simulation approach. Pharmaceutics. 2021;13(11):1970. doi:10.3390/pharmaceutics13111970
   PubMed Web of Science ®Google Scholar
• Brunet M, Van Gelder T, Asberg A, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261–307. doi:10.1097/FTD.0000000000000640
   PubMed Web of Science ®Google Scholar
• Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015;98(1):19–24. doi:10.1002/cpt.113
   PubMed Web of Science ®Google Scholar
• Schütte-Nütgen K, Thölking G, Steinke J, et al. Fast Tac metabolizers at risk - it is time for a C/D ratio calculation. J Clin Med. 2019;8(5):587. doi:10.3390/jcm8050587
   PubMed Web of Science ®Google Scholar
• van Gelder T, Meziyerh S, Swen JJ, de Vries APJ, Moes DJAR. The clinical impact of the C0/D ratio and the CYP3A5 genotype on outcome in tacrolimus treated kidney transplant recipients. Front Pharmacol. 2020;11:1142. doi:10.3389/fphar.2020.01142
   PubMed Web of Science ®Google Scholar
• Kuypers DRJ. “What do we know about tacrolimus pharmacogenetics in transplant recipients?”. Pharmacogenomics. 2018;19(7):593–597. doi:10.2217/pgs-2018-0035
   PubMed Web of Science ®Google Scholar
• Eskandari SK, Gaya da Costa M, Faria B, et al. An interleukin 6-based genetic risk score strengthened with interleukin 10 polymorphisms associated with long-term kidney allograft outcomes. Am J Transplant. 2022;22(Suppl. 4):45–57. doi:10.1111/ajt.17212
   PubMedGoogle Scholar
• Stipp MC, Acco A. Involvement of cytochrome P450 enzymes in inflammation and cancer: a review. Cancer Chemother Pharmacol. 2021;87(3):295–309. doi:10.1007/s00280-020-04181-2
   PubMed Web of Science ®Google Scholar
• Lenoir C, Rollason V, Desmeules JA, Samer CF. Influence of inflammation on cytochromes P450 activity in adults: a systematic review of the literature. Front Pharmacol. 2021;12:733935. doi:10.3389/fphar.2021.733935
   PubMed Web of Science ®Google Scholar
• Gorski JC, Hall SD, Becker P, Affrime MB, Cutler DL, Haehner-Daniels B. In vivo effects of interleukin-10 on human cytochrome P450 activity. Clin Pharmacol Ther. 2000;67(1):32–43. doi:10.1067/mcp.2000.103860
   PubMed Web of Science ®Google Scholar
• Chen Z, Cheng X, Zhang L, et al. The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients. Pharmacol Rep. 2021;73(5):1418–1426. doi:10.1007/s43440-021-00288-2
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Greene T, et al. Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–254. doi:10.7326/0003-4819-145-4-200608150-00004
   PubMed Web of Science ®Google Scholar
• Losito A, Kalidas K, Santoni S, Jeffery S. Association of interleukin-6 -174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int. 2003;64(2):616–622. doi:10.1046/j.1523-1755.2003.00119.x
   PubMed Web of Science ®Google Scholar
• Korbie DJ, Mattick JS. Touchdown PCR for increased specificity and sensitivity in PCR amplification. Nat Protoc. 2008;3(9):1452–1456. doi:10.1038/nprot.2008.133
   PubMed Web of Science ®Google Scholar
• Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H, et al. Association between IL-10 gene promoter polymorphisms (-592 A/C, -819 T/C, -1082 A/G) and susceptibility to HBV infection in an Iranian population. Hepat Mon. 2016;16(2):e32427. doi:10.5812/hepatmon.41984
   PubMed Web of Science ®Google Scholar
• Rad R, Dossumbekova A, Neu B, et al. Cytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation, and host specific colonisation during Helicobacter pylori infection. Gut. 2004;53(8):1082–1089. doi:10.1136/gut.2003.029736
   PubMed Web of Science ®Google Scholar
• Lauschke VM, Zhou Y, Ingelman-Sundberg M. Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. Pharmacol Ther. 2019;197:122–152. doi:10.1016/j.pharmthera.2019.01.002
   PubMed Web of Science ®Google Scholar
• Stefanović NZ, Veliĉković-Radovanović RM, Danković KS, et al. Combined effect of inter- and intrapatient variability in tacrolimus exposure on graft impairment within a 3-year period following kidney transplantation: a single-center experience. Eur J Drug Metab Pharmacokinet. 2020;45(6):749–760. doi:10.1007/s13318-020-00644-2
   PubMed Web of Science ®Google Scholar
• Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102(7):1369–1376. doi:10.1172/JCI2629
   PubMed Web of Science ®Google Scholar
• Alves LV, Martins SR, Simões E Silva AC, Cardoso CN, Gomes KB, Mota APL. TNF, IL-6, and IL-10 cytokines levels and their polymorphisms in renal function and time after transplantation. Immunol Res. 2020;68(5):246–254. doi:10.1007/s12026-020-09147-3
   PubMed Web of Science ®Google Scholar
• Kistner TM, Pedersen BK, Lieberman DE. Interleukin 6 as an energy allocator in muscle tissue. Nat Metab. 2022;4(2):170–179. doi:10.1038/s42255-022-00538-4
   PubMedGoogle Scholar
• Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813(5):878–888. doi:10.1016/j.bbamcr.2011.01.034
   PubMed Web of Science ®Google Scholar
• Schaper F, Rose-John S. Interleukin-6: biology, signaling and strategies of blockade. Cytokine Growth Factor Rev. 2015;26(5):475–487. doi:10.1016/j.cytogfr.2015.07.004
   PubMed Web of Science ®Google Scholar
• Baran P, Hansen S, Waetzig GH, et al. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling. J Biol Chem. 2018;293(18):6762–6775. doi:10.1074/jbc.RA117.001163
   PubMed Web of Science ®Google Scholar
• Rose-John S. Interleukin-6 signalling in health and disease. F1000Res. 2020;9:F1000 Faculty Rev-1013. doi:10.12688/f1000research.26058.1
   PubMedGoogle Scholar
• Chavant A, Fonrose X, Gautier-Veyret E, Hilleret MN, Roustit M, Stanke-Labesque F. Variability of tacrolimus trough concentration in liver transplant patients: which role of inflammation? Pharmaceutics. 2021;13(11):1960. doi:10.3390/pharmaceutics13111960
   PubMed Web of Science ®Google Scholar
• Seyhun Y, Ciftci HS, Kekik C, et al. Genetic association of interleukin-2, interleukin-4, interleukin-6, transforming growth factor-β, tumour necrosis factor-α and blood concentrations of calcineurin inhibitors in Turkish renal transplant patients. Int J Immunogenet. 2015;42(3):147–160. doi:10.1111/iji.12192
   PubMed Web of Science ®Google Scholar
• Kotowski M, Bogacz A, Bartkowiak-Wieczorek J, et al. Effect of Interleukin-6 polymorphism on function of the renal allograft funtion and efficacy of immunosuppressive therapy. Farmacia. 2018;66(5):791–797. doi:10.31925/farmacia.2018.5.8
   Web of Science ®Google Scholar
• Enokiya T, Nishikawa K, Hamada Y, Ikemura K, Sugimura Y, Okuda M. Temporary decrease in tacrolimus clearance in cytochrome P450 3A5 non-expressors early after living donor kidney transplantation: effect of interleukin 6-induced suppression of the cytochrome P450 3A gene. Basic Clin Pharmacol Toxicol. 2021;128(3):525–533. doi:10.1111/bcpt.13539
   PubMed Web of Science ®Google Scholar
• Shah RR, Smith RL. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine. Drug Metab Dispos. 2015;43(3):400–410. doi:10.1124/dmd.114.061093
   PubMed Web of Science ®Google Scholar
• Stanke-Labesque F, Gautier-Veyret E, Chhun S, Guilhaumou R. French Society of Pharmacology and Therapeutics. Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment. Pharmacol Ther. 2020;215:107627. doi:10.1016/j.pharmthera.2020.107627
   PubMed Web of Science ®Google Scholar
• Ouyang W, O'Garra A. IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation. Immunity. 2019;50(4):871–891. doi:10.1016/j.immuni.2019.03.020
   PubMed Web of Science ®Google Scholar
• Saxena A, Khosraviani S, Noel S, Mohan D, Donner T, Hamad AR. Interleukin-10 paradox: a potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine. 2015;74(1):27–34. doi:10.1016/j.cyto.2014.10.031
   PubMed Web of Science ®Google Scholar
• Steen EH, Wang X, Balaji S, Butte MJ, Bollyky PL, Keswani SG. The role of the anti-inflammatory cytokine interleukin-10 in tissue fibrosis. Adv Wound Care (New Rochelle). 2020;9(4):184–198. doi:10.1089/wound.2019.1032
   PubMed Web of Science ®Google Scholar
• Bedke T, Muscate F, Soukou S, Gagliani N, Huber S. IL-10-producing T cells and their dual functions. Semin Immunol. 2019;44:101335. doi:10.1016/j.smim.2019.101335
   PubMed Web of Science ®Google Scholar
• Li D, Zhu JY, Gao J, Wang X, Lou YQ, Zhang GL. Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. Clin Chim Acta. 2007;383(1–2):133–139. doi:10.1016/j.cca.2007.05.008
   PubMed Web of Science ®Google Scholar
• Li CJ, Li L, Lin L, et al. Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients. PLoS One. 2014;9(1):e86206. doi:10.1371/journal.pone.0086206
   PubMed Web of Science ®Google Scholar
• Bogacz A, Polaszewska A, Bartkowiak-Wieczorek J, et al. The effect of genetic variations for interleukin-10 (IL-10) on the efficacy of immunosuppressive therapy in patients after kidney transplantation. Int Immunopharmacol. 2020;89(Pt A):107059. doi:10.1016/j.intimp.2020.107059
   PubMedGoogle Scholar
• Khaleel B, Yousef AM, Al-Zoubi MS, et al. Impact of genetic polymorphisms at the promoter area of IL-10 gene on tacrolimus level in Jordanian renal transplantation recipients. J Med Biochem. 2022;41(3):327–334. doi:10.5937/jomb0-33343
   PubMed Web of Science ®Google Scholar
• Cheng X, Chen Y, Zhang L, et al. Influence of CYP3A5, IL-10 polymorphisms and metabolism rate on tacrolimus exposure in renal post-transplant recipients. Pharmacogenomics. 2022;(18):961–972. doi:10.2217/pgs-2022-0123
   PubMed Web of Science ®Google Scholar
• Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822–1832. doi:10.1038/s41591-019-0675-0
   PubMed Web of Science ®Google Scholar
• Djamali A, Samaniego M, Muth B, et al. Medical care of kidney transplant recipients after the first posttransplant year. Clin J Am Soc Nephrol. 2006;1(4):623–640. doi:10.2215/CJN.01371005
   PubMed Web of Science ®Google Scholar
• Netea MG, Balkwill F, Chonchol M, et al. A guiding map for inflammation. Nat Immunol. 2017;18(8):826–831. doi:10.1038/ni.3790
   PubMed Web of Science ®Google Scholar